Kbio Labs

At a glance

Kbio Labs filed 48 disclosures in the last 12 months, including 8 insider, 7 5% holder and 1 issuance. The most recent key filing was on Sep 4.

Revenue for 2025 was ₩87.3B, up 14.1% on 2024. Operating margin was 1.7% against 1% a year earlier. Debt was 16% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩21.7B and operating profit of ₩324M.

The 2025 annual report lists 38 employees with an average tenure of 3.2 years and average pay of ₩49.4M. Its 6 directors and auditors were paid ₩51M each on average. It paid no cash dividend for 2025. ㈜미래아이앤지 and related parties held 33.09% at year end.

From the 2025 annual report

Staff: 38 (22 men, 16 women), of whom 0 on fixed-term contracts. Total pay for the year: ₩1.9B. Directors and auditors: 6, paid ₩305M in total.

No cash dividend was paid for 2025.

Largest shareholder

㈜미래아이앤지 holds 27.58%; with 1 related party the group holds 33.09% of common shares at year end.

Auditor: 삼화회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary